SCHEMBL1961607

SCHEMBL1961607

O=C(O)CNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O

nearest known ligand 0.76

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 16/20 0.76
CRBN Q96SW2 16/20 0.76
HDAC1 Q13547 1/20 0.62
HDAC2 Q92769 1/20 0.62
IKZF3 Q9UKT9 2/20 0.61
TNF P01375 1/20 0.61
IL1B P01584 1/20 0.61
TBXA2R P21731 1/20 0.61
IKZF1 Q13422 1/20 0.61
STAT3 P40763 2/20 0.59
ALDH1A1 P00352 1/20 0.58
CHRM2 P08172 1/20 0.58
OPRM1 P35372 1/20 0.58
CYP1A2 P05177 1/20 0.58
TSHR P16473 1/20 0.58
TDP1 Q9NUW8 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22649829 1.00 DDB1 (0.76) DDB1CRBNHDAC1HDAC2IKZF3
SCHEMBL29402619 1.00 DDB1 (0.76) DDB1CRBNHDAC1HDAC2IKZF3
Hydrochloric Acid SCHEMBL29262211 1.00 DDB1 (0.76) DDB1CRBNHDAC1HDAC2IKZF3
SCHEMBL21554630 0.92 CRBN (0.73) DDB1CRBNHDAC1HDAC2IKZF3
SCHEMBL29378386 0.91 DDB1 (0.71) DDB1CRBNHDAC1HDAC2IKZF3
SCHEMBL19481342 0.91 DDB1 (0.71) DDB1CRBNHDAC1HDAC2IKZF3
SCHEMBL21998325 0.91 DDB1 (0.76) DDB1CRBNHDAC1HDAC2IKZF3
SCHEMBL24621134 0.90 DDB1 (0.77) DDB1CRBNHDAC1HDAC2IKZF3
SCHEMBL20242499 0.90 CRBN (0.73) DDB1CRBNHDAC1HDAC2IKZF3
SCHEMBL1962899 0.89 DDB1 (0.69) DDB1CRBNHDAC1HDAC2IKZF3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070049618-A1 Isoindole-imide compounds and compositions comprising and methods of using the same CELGENE CORPORATION 2007-03-01 US claimed
US-20260125382-A1 COMPOUNDS FOR INHIBITING OR DEGRADING CDK2 AND/OR CDK9 AND MEDICINAL USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2026-05-07 US disclosed
EP-4736882-A2 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE Cullgen (Shanghai), Inc. (CN) 2026-05-06 EP disclosed
US-20260116867-A1 PROTEOLYSIS TARGETING CHIMERAS FOR HUMAN PREGNANE X RECEPTOR AND FOR DEGRADATION OF GSPT1 ST JUDE CHILDRENS RES HOSPITAL (US) 2026-04-30 US disclosed
US-20260115297-A1 HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 ICAHN SCHOOL MED MOUNT SINAI (US) 2026-04-30 US disclosed
US-20260108474-A1 PAMAM-BASED NANOPARTICLE PROTEIN DEGRADATION SYSTEM AND METHOD OF PREPARATION AND USE THEREOF QILU UNIV OF TECHNOLOGY SHANDONG ACADEMY OF SCIENCES (CN) 2026-04-23 US disclosed
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 EP disclosed
US-20260085058-A1 DEGRADERS OF SON OF SEVENLESS HOMOLOG 1 YUAN YU (US) 2026-03-26 US disclosed
EP-3725771-B1 ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF UNIV SHANGHAI TECHNOLOGY (CN) 2026-02-04 EP disclosed
US-20260027217-A1 DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2026-01-29 US disclosed
US-8481568-B2 Isoindole-imide compounds and compositions comprising and methods of using the same CELGENE CORPORATION (US) 2013-07-09 US disclosed
US-8481568-B2 Isoindole-imide compounds and compositions comprising and methods of using the same CELGENE CORPORATION (US) 2013-07-09 US disclosed
US-20110144158-A1 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME SEPRACOR INC. 2011-06-16 US disclosed
US-20110144158-A1 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME SEPRACOR INC. 2011-06-16 US disclosed
EP-1919892-A2 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION (US) 2008-05-14 EP disclosed
WO-2007027527-A2 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION (US) 2007-03-08 WO disclosed
WO-2007027527-A2 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION (US) 2007-03-08 WO disclosed
US-20070049618-A1 Isoindole-imide compounds and compositions comprising and methods of using the same CELGENE CORPORATION 2007-03-01 US disclosed
US-20070049618-A1 Isoindole-imide compounds and compositions comprising and methods of using the same CELGENE CORPORATION 2007-03-01 US disclosed
US-20070049618-A1 Isoindole-imide compounds and compositions comprising and methods of using the same CELGENE CORPORATION 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027217-A1 DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF ALK, IGF1R, PDGFRB DDB1 3876/4885CRBN 563/4885HDAC1 3422/4885
US-20110144158-A1 ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME SI, CYP3A5, CYP2D6 DDB1 4509/4885CRBN 2589/4885HDAC1 958/4885
US-20260125382-A1 COMPOUNDS FOR INHIBITING OR DEGRADING CDK2 AND/OR CDK9 AND MEDICINAL USE THEREOF CDK9, CDK20, CDK19 DDB1 534/4885CRBN 548/4885HDAC1 82/4885
US-20260115297-A1 HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 TTK, ITK, CLK1 DDB1 2640/4885CRBN 1072/4885HDAC1 969/4885
US-20070049618-A1 Isoindole-imide compounds and compositions comprising and methods of using the same SI, CYP3A5, CYP2D6 DDB1 4509/4885CRBN 2589/4885HDAC1 958/4885
US-20260108474-A1 PAMAM-BASED NANOPARTICLE PROTEIN DEGRADATION SYSTEM AND METHOD OF PREPARATION AND USE THEREOF MDM2, TP53, SKP2 DDB1 795/4885CRBN 27/4885HDAC1 838/4885
US-20260085058-A1 DEGRADERS OF SON OF SEVENLESS HOMOLOG 1 SOS1, KRAS, SOS2 DDB1 484/4885CRBN 71/4885HDAC1 3370/4885
US-20260116867-A1 PROTEOLYSIS TARGETING CHIMERAS FOR HUMAN PREGNANE X RECEPTOR AND FOR DEGRADATION OF GSPT1 NR3C1, GPER1, NR1H4 DDB1 860/4885CRBN 1192/4885HDAC1 478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.